Inflammation Score Predicts Cancer Survival
Author Information
Author(s): Proctor M J, Morrison D S, Talwar D, Balmer S M, O'Reilly D S J, Foulis A K, Horgan P G, McMillan D C
Primary Institution: University Department of Surgery, Faculty of Medicine-University of Glasgow
Hypothesis
Does the modified Glasgow Prognostic Score (mGPS) predict cancer survival independent of tumor site?
Conclusion
The mGPS is a powerful prognostic factor for cancer survival, independent of tumor site.
Supporting Evidence
- An elevated mGPS was associated with reduced 5-year overall and cancer-specific survival.
- Patients with a low albumin concentration had poor survival in some cancers.
- An mGPS of 2 was associated with a 160% reduction in overall and cancer-specific survival.
Takeaway
Doctors can use a special score based on inflammation to help predict how long cancer patients might live, no matter where their cancer is.
Methodology
The study analyzed blood samples from 21,669 cancer patients to assess the relationship between mGPS, biochemical parameters, tumor site, and survival.
Potential Biases
Patients with concurrent morbidity may have influenced the results due to elevated inflammatory markers.
Limitations
The study may not represent all cancer patients as it only included those with specific blood tests performed.
Participant Demographics
The cohort included 9608 patients with a median age of 75 years, with 53% female and 47% male.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website